Journal of Medical Economics
Volume 27, 2024 - Issue 1
Open access
1,098
Views
0
CrossRef citations to date
0
Altmetric
Oncology
Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results
Olalekan O. Oluwolea Vanderbilt University Medical Center, Nashville, TN, USACorrespondence[email protected]
https://orcid.org/0000-0001-8525-9641
, https://orcid.org/0000-0001-8525-9641
Markqayne D. Rayb Kite, A Gilead Company, Santa Monica, CA, USA
, Neil Daviesc Mtech Access, Cheadle Hulme, UK
, Rory Bradfordc Mtech Access, Cheadle Hulme, UK
, Calum Jonesc Mtech Access, Cheadle Hulme, UK
, Anik R. Patelb Kite, A Gilead Company, Santa Monica, CA, USA
& Frederick L. Locked H. Lee Moffitt Cancer Center, Tampa, FL, USAhttps://orcid.org/0000-0001-9063-6691
show all
Pages 230-239
|
Received 23 Nov 2023, Accepted 11 Jan 2024, Published online: 13 Feb 2024
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.